Biologics News
KOMZIFTI® (ziftomenib), FDA-Approved for Treatment of Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia, Available at Biologics by McKesson
Cary, N.C. , Nov. 13, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease
INLURIYO™ (imlunestrant) FDA-Approved for Treatment of ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson
Cary, N.C. , Oct. 1, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease
PALSONIFY™ (paltusotine), FDA-Approved for Treatment of Adults with Acromegaly Who Had an Inadequate Response to Surgery and/or for Whom Surgery Is Not an Option, Available at Biologics by McKesson
Cary, N.C. , Sept. 25, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease
Precigen Selects McKesson to Support Specialty Pharmacy and Patient Hub Services for Launch of Novel Immunotherapy
CARY, N.C., Sept. 25, 2025 – Biologics by McKesson, in partnership with Inspirogene by McKesson, has been chosen by Precigen
InspiroGene by McKesson Selected as the Specialty Pharmacy Partner for Iovance’s Amtagvi®—First Cell Therapy Approved for Solid Tumors
CARY, N.C., Sept. 24, 2025 – Biologics by McKesson is proud to announce the launch of Amtagvi® (lifileucel), the newest
WAYRILZ™ (rilzabrutinib), FDA-Approved for Treatment of Adults with Immune Thrombocytopenia, Available at Biologics by McKesson
Cary, N.C. , Sept. 10, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease